Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Daniel Brungs"'
Autor:
Branka Powter, Heena Sareen, Mila Sajinovic, Joseph W. Po, Sarah A Jeffreys, Kieran F. Scott, Eng-Siew Koh, Tara L. Roberts, Daniel Brungs, Paul de Souza, Adam Cooper, Therese M. Becker, Joey Yusof Vessey
Publikováno v:
Journal of Cancer Research and Clinical Oncology
The TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers includi
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 2, Pp 962-967 (2020)
Case Reports in Oncology, Vol 13, Iss 2, Pp 962-967 (2020)
Non-small cell lung cancer (NSCLC) is characterised by diffuse metastases, with common sites being the brain, liver, bones, and adrenal glands. Small bowel metastasis from NSCLC is a rare phenomenon, particularly in patients with an adenocarcinoma hi
Autor:
Wanxing Chai-Ho, Jenny H. Lee, Ignacio Melero, Andrew Haydon, Nikhil I. Khushalani, Jose Lutzky, Andrew F. Hill, Gregory A. Daniels, Muhammad Alamgeer, Ragini R. Kudchadkar, Dimitrios Colevas, Ann Silk, Piyush Sheladia, Daniel Brungs, Shui He, Praveen K. Bommareddy, Frances A. Collichio, Samantha Bowyer, Céleste Lebbé, Michael R. Migden, Danny Rischin, Jean-jaques Grob, Matthew G. Fury, Claudia Andreu-Vieyra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe prognosis for advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains poor for many patients with the disease despite approval of the anti-PD1 antibodies cemiplimab and pembrolizumab.1 2 RP1 is an oncolytic virus (HSV-1
Autor:
Lucy Haggstrom, Robert Winn, Soni Putnis, James Chen, Morteza Aghmesheh, Elias H. Nasser, Sharlyn Kang, Daniel Brungs
Publikováno v:
ANZ Journal of Surgery. 90:2490-2495
Background As treatments for rectal cancer improve with developments in surgical techniques, radiotherapy and chemotherapy, the nature of recurrences are evolving. We used a comprehensive database of a large Australian population with stage I-III rec
Publikováno v:
Clinical Lung Cancer. 21:e261-e264
Neurofibromatosis type 1 is an autosomal dominant condition that classically presents with cafe au lait spots, cutaneous neurofibromas, axillary and inguinal freckling, and iris Lisch nodules. Patients diagnosed with NF-1 have an increased risk of ma
Autor:
Benjamin Thomas, Tuan Anh Duong, Gurdeep Parmar, Daniel Brungs, Morteza Aghmesheh, Lucy Haggstrom
Publikováno v:
Melanoma Research. 29:533-538
Disseminated intravascular coagulation is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficul
Autor:
Morteza Aghmesheh, Lorraine A. Chantrill, Peter Grimison, Katrin Marie Sjoquist, Samuel Robinson, Therese M. Becker, Kate Wilson, Daniel Brungs, Rachel Woodford, Carly Leighton, Val Gebski
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 18
BACKGROUND Advanced biliary tract cancer (ABTC) is a highly aggressive malignancy, with a 5-year overall survival of
Autor:
Richard David Ranson, Paul de Souza, Morteza Aghmesheh, Marie Ranson, Rebecca Jokela, Philip Clingan, Stephen P. Ackland, Daniel Brungs, Suzanne Parker, M B Garg
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 15:151-157
Background 5-Fluorouracil (5-FU) is administered with leucovorin (LV) to enhance clinical activity. However, simultaneous administration is not feasible due to their chemical incompatibility, so conditions for the maximum possible beneficial interact
Autor:
Vinay Murthy, Erin Saricilar, Daniel Brungs, Joseph W. Po, Paul de Souza, Adam Cooper, Farhad Azimi, Bavanthi Balakrishnar, Yafeng Ma, Therese M. Becker
Publikováno v:
Methods in Molecular Biology ISBN: 9781071612040
The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a68adbd5c85107e65f658d858fb3485
https://doi.org/10.1007/978-1-0716-1205-7_17
https://doi.org/10.1007/978-1-0716-1205-7_17
Autor:
Boris Kasparov, Philip Clingan, Natalia Fadeeva, Andrey Akopov, Margaret McGrath, Vasiliy Oschepkov, Vadim Kozlov, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, D. Harris, Fedor Moiseenko, Andrea Tazbirkova, Piotr Koralewski, Chaiyut Charoentumn, Iwona Lugowska, Nadezhda Kovalenko, Dariusz Kowalski, Daniel Brungs, Andrew Mant, Rahul Ladwah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors to restore an anti-tumo